捷克中欧理工学院招聘白血病、淋巴癌和非编码RNA方向博士后

MENTOR: MAREK MRÁZ, MSC., M.D., PH.D.
The newly established laboratory of Marek Mraz, M.D., Ph.D. at the University Hospital Brno and Central European Institute of Technology (Masaryk University, Brno, Czech Rep.) is recruiting a Postdoctoral Fellow. The research will focus on THE ROLE OF MICROENVIRONMENT INTERACTIONS AND NON-CODING RNAS IN THE BIOLOGY OF B-CELL MALIGNANCIES. The research project is supported by the European Hematology Association and Czech Science Foundation.
PROJECT:
The aim of the laboratory is to study the biology of hematological malignancies with a focus on molecular pathways that regulate malignant immune cells’ microenvironmental interactions. It is now understood that pathways like the B-cell receptor (BCR) signaling are deregulated during the onset of most B cell leukemias and lymphomas. The BCR pathway is considered the most promising target for therapy in B cell malignancies. We showed that the aberrant expression of non-coding RNAs is likely to be a crucial event in the deregulation of the BCR pathway. Non-coding RNAs, especially microRNAs (miRNAs), represent an important layer of cell function regulation. For numerous pathological processes the principal deregulation takes place at the level of such non-coding RNAs in B cell malignancies (Mraz et al., Leukemia, 2009; Mraz et al., Blood, 2012; Mraz et al., Blood, 2014). We have recently performed studies which revealed that microRNAs regulate the B-cell receptor signaling which represents the essential pathway for the normal and malignant B cells fate (Mraz and Kipps, 2013; Mraz et al., 2014). Overall, the role of non-coding RNAs in microenvironmental interactions and immune cell activation has not been elucidated yet. This is a very interesting question in biomedical research since the interactions within the immune niche context are the basis for relapse, persisting minimal residual disease and cancer stem cells in leukemias and lymphomas, failure of the immune system to target cancer cells, cell resistance to therapy and, in principle, the incurability of many hematological malignancies. The researcher will perform studies utilizing a large database of primary patient samples, using both classical techniques of molecular biology and novel approaches like next-generation sequencing (Illumina).

Candidates should have a PhD or MD/PhD with experience in cancer biology, cell biology, or molecular biology. Applicant should possess the ability to conduct independent research in the biological sciences. Our institute provides outstanding laboratory facilities and a highly supportive environment. The successful applicant will work in a team of young investigators and will also have the opportunity to supervise doctoral/diploma students. The research will be conducted at the CENTER OF MOLECULAR BIOLOGY AND GENE THERAPY (University Hospital Brno, Dept. Of Int. Medicine, Hematology and Oncology) and CEITEC MASARYK UNIVERSITY.
 START DATE: OCTOBER-DECEMBER

OTHER INFORMATION:
The mission of the institute is to advance the understanding of the underlying molecular and cellular mechanisms of hematological malignancies. Our laboratory is located in Children‘s Hospital Brno (Cernopolni 9, city center) and also in University Campus (Kamenice 5, 4kms outside the city center). The campus provides a vibrant, multidisciplinary and highly collaborative scientific environment. The lab is located in Brno, the second-largest city in Czech Rep. that hosts 6 major universities with the biggest concentration of biomedical research in this European region. Brno is one of the major cultural hubs, with a vibrant and lively atmosphere housing ~60000 students. The city has a very good public transport and plenty of interesting places to visit within the reach of trains. Located in the heart of Europe, Brno is within small distance of several major cities (Prague, Vienna, Bratislava, Budapest) and close to international airports (Prague, Vienna). …